Drug intelligence / Profile preview

OVAREVIVE II

Development stage: Unknown
Lead developer: Zhejiang Ovarevive Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

OVAREVIVE II is a multi-ingredient combination product developed for the management of diminished ovarian reserve (DOR). It is a successor to the original OVAREVIVE formulation and is typically composed of dehydroepiandrosterone (DHEA), coenzyme Q10 (CoQ10), and melatonin. The product is designed to improve the microenvironment of the ovaries, enhance mitochondrial function in oocytes, and provide antioxidant protection, thereby potentially improving clinical outcomes for women undergoing assisted reproductive technology (ART). It is currently being evaluated in clinical trials sponsored by institutions such as Zhejiang Hospital to assess its efficacy and safety in patients with DOR.

Brand names: OVAREVIVE II
Other names: Ovarevive 2Ovarevive2Ovarevive-2欧维复 II

Targets

ND1 (Mitochondrial electron transport chain complex I)MTNR1A (MT1)AR (Adrenergic receptors)

Beyond the preview

Go deeper on OVAREVIVE II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVAREVIVE II.

Explore the full profile